Imricor Medical Systems (ASX:IMR) said it completed the first-ever pre-clinical animal study in vivo pulsed field ablation in the ventricle under real-time magnetic resonance imaging (MRI) guidance in an interventional cardiac magnetic resonance imaging laboratory, according to a Monday Australian bourse filing.
The procedure was performed using the firm's second-generation Vision-MR ablation catheter at its iCMR Design Center, validating its technology for integrating pulsed field ablation energy with real-time MRI visualization.
The firm's shares fell 1% in recent trading on Monday.